Kristen Slaoui

Kristen Slaoui currently serves as the Chief Corporate Development Officer at Galderma and holds positions on the Board of Directors for Advancing Innovation in Dermatology, Inc., and as a Scientific Advisory Board Member & Board Observer for Kinaset Therapeutics. Slaoui previously served on the Board of Directors for Villaris Therapeutics, which was acquired by Incyte Corporation in 2022. Slaoui's extensive experience at GSK includes roles as Vice President & Head of Business Development in various capacities, as well as Director of Corporate Development focusing on mergers and acquisitions. Earlier career highlights include significant contributions at Merck Research Laboratories in neuroscience drug discovery and a principal investigator role leading novel drug discovery efforts at GSK in respiratory and inflammation therapeutic areas. Slaoui's academic credentials include a PhD in Physiology from The Johns Hopkins University and a postdoctoral fellowship in Pharmacology from the University of Washington.